Harvard Bioscience, Inc.
Harvard Bioscience, Inc. Fundamental Analysis
Harvard Bioscience, Inc. (HBIO) shows weak financial fundamentals with a PE ratio of -0.48, profit margin of -61.62%, and ROE of -1.99%. The company generates $0.1B in annual revenue with weak year-over-year growth of -16.14%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -257.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HBIO's fundamental strength across five key dimensions:
Efficiency Score
WeakHBIO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentHBIO trades at attractive valuation levels.
Growth Score
WeakHBIO faces weak or negative growth trends.
Financial Health Score
WeakHBIO carries high financial risk with limited liquidity.
Profitability Score
WeakHBIO struggles to sustain strong margins.
Key Financial Metrics
Is HBIO Expensive or Cheap?
P/E Ratio
HBIO trades at -0.48 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, HBIO's PEG of -0.08 indicates potential undervaluation.
Price to Book
The market values Harvard Bioscience, Inc. at 1.85 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.23 times EBITDA. This is generally considered low.
How Well Does HBIO Make Money?
Net Profit Margin
For every $100 in sales, Harvard Bioscience, Inc. keeps $-61.62 as profit after all expenses.
Operating Margin
Core operations generate -57.55 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.99 in profit for every $100 of shareholder equity.
ROA
Harvard Bioscience, Inc. generates $-69.03 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Harvard Bioscience, Inc. generates limited operating cash flow of $8.33M, signaling weaker underlying cash strength.
Free Cash Flow
Harvard Bioscience, Inc. produces free cash flow of $6.90M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.15 in free cash annually.
FCF Yield
HBIO converts 26.47% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.85
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.81
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.99
vs 25 benchmark
ROA
Return on assets percentage
-0.69
vs 25 benchmark
ROCE
Return on capital employed
-2.13
vs 25 benchmark
How HBIO Stacks Against Its Sector Peers
| Metric | HBIO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.48 | 29.43 | Better (Cheaper) |
| ROE | -199.43% | 800.00% | Weak |
| Net Margin | -61.62% | -20145.00% (disorted) | Weak |
| Debt/Equity | 3.04 | 0.30 | Weak (High Leverage) |
| Current Ratio | 0.81 | 4.64 | Weak Liquidity |
| ROA | -69.03% | -17936.00% (disorted) | Weak |
HBIO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Harvard Bioscience, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-29.63%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-129.87%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-84.46%
Industry Style: Defensive, Growth, Innovation
Declining